Summary
GlobalData has released its pharma report, “Non-Small Cell Lung Cancer (NSCLC) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing NSCLC Market. The report identifies and analyses the key companies shaping and driving the global NSCLC market. The report provides insight into the competitive NSCLC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
Scope
- Investigation of current and future market competition for NSCLC
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of NSCLC sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving NSCLC market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global NSCLC market landscape? Identify, understand and capitalize
Companies Mentioned
Roche/Genentech
Eli Lilly
Pfizer
AstraZeneca
Bristol-Myers Squibb
Merck & Co.
Novartis
Boehringer Ingelheim
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 6
2.3 Upcoming Related Reports 7
3 Market Outlook 8
3.1 Global Markets 8
3.1.1 Forecast 8
3.1.2 Drivers and Barriers - Global Issues 12
4 Current and Future Players 16
4.1 Overview 16
4.2 Trends in Corporate Strategy 21
4.3 Company Profiles 24
4.3.1 Roche/Genentech 24
4.3.2 Eli Lilly 27
4.3.3 Pfizer 30
4.3.4 AstraZeneca 33
4.3.5 Bristol-Myers Squibb 36
4.3.6 Merck & Co. 39
4.3.7 Novartis 42
4.3.8 Boehringer Ingelheim 44
5 Appendix 47
5.1 Bibliography 47
5.2 Abbreviations 93
5.3 Methodology 104
5.4 Forecasting Methodology 104
5.4.1 Diagnosed NSCLC Patients 104
5.4.2 Percent Drug-Treated Patients 105
5.4.3 Drugs Included in Each Therapeutic Class 105
5.4.4 Launch and Patent Expiry Dates 108
5.4.5 General Pricing Assumptions 110
5.4.6 Individual Drug Assumptions 112
5.4.7 Generic Erosion 126
5.4.8 Pricing of Pipeline Agents 126
5.5 Primary Research - KOLs 131
5.5.1 KOLs 131
5.6 About the Authors 135
5.6.1 Analyst 135
5.6.2 Therapy Area Director 135
5.6.3 Epidemiologist 136
5.6.4 Global Head of Healthcare 136
5.7 About GlobalData 138
5.8 Disclaimer 138
1.1 List of Tables
Table 1: NSCLC - Global Drivers and Barriers, 2015‒2025 12
Table 2: Key Companies in the NSCLC Market in the 8MM, 2015-2025 19
Table 3: Roche/Genentech’s NSCLC Portfolio Assessment, 2016 26
Table 4: Eli Lilly’s NSCLC Portfolio Assessment, 2016 29
Table 5: Pfizer’s NSCLC Portfolio Assessment, 2016 32
Table 6: AZ’s NSCLC Portfolio Assessment, 2016 35
Table 7: BMS’ NSCLC Portfolio Assessment, 2016 38
Table 8: Merck & Co.’s NSCLC Portfolio Assessment, 2016 41
Table 9: Novartis’ NSCLC Portfolio Assessment, 2016 43
Table 10: BI’s NSCLC Portfolio Assessment, 2016 46
Table 11: Key Launch Dates - Part I 108
Table 12: Key Launch Dates - Part II 109
Table 13: Key Patent Expiries 110
Table 14 Average Body Weight and Surface Area Across the 8MM 111
Table 15: Average Cost of Therapy of Alimta in the 8MM 113
Table 16: Average Cost of Therapy of Alecensa in the 8MM 114
Table 17: Average Cost of Therapy of Avastin 115
Table 18: Average Cost of Therapy of Cyramza 115
Table 19: Average Cost of Therapy of Gilotrif 116
Table 20: Average Cost of Therapy of Iressa 117
Table 21: Average Cost of Therapy of Portrazza 118
Table 22: Average Cost of Therapy of Tagrisso 119
Table 23: Average Cost of Therapy of Tarceva 120
Table 24: Average Cost of Therapy of Vargatef 120
Table 25: Average Cost of Therapy of Xalkori 121
Table 26: Average Cost of Therapy of Zykadia 122
Table 27: Average Cost of Therapy of Keytruda 123
Table 28: Average Cost of Therapy of Opdivo 124
Table 29: Average Cost of Therapy of Tecentriq 125
Table 30: Average Cost of Therapy of Conmana 126
Table 31: High-Prescribing Physicians Surveyed by Country 134
1.2 List of Figures
Figure 1: Global Sales for NSCLC (8MM), 2015-2025 9
Figure 2: Global Sales for NSCLC (8MM), 2015-2025 10
Figure 3: Global Sales for NSCLC (8MM), 2015-2025 11
Figure 4: Global Sales of Branded Products for NSCLC by Company, 2015-2025 20
Figure 5: Company Portfolio Gap Analysis in NSCLC, 2015-2025 21
Figure 6: Roche/Genentech SWOT Analysis in NSCLC, 2016 27
Figure 7: Eli Lilly SWOT Analysis in NSCLC, 2016 30
Figure 8: Pfizer SWOT Analysis in NSCLC, 2016 33
Figure 9: AZ SWOT Analysis in NSCLC, 2016 36
Figure 10: BMS SWOT Analysis in NSCLC, 2016 39
Figure 11: Merck & Co. SWOT Analysis in NSCLC, 2016 42
Figure 12: Novartis SWOT Analysis in NSCLC, 2016 44
Figure 13: BI SWOT Analysis in NSCLC, 2016 46
